Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

References

• Pagano L, Pulsoni A, Tosti ME, et al. Clinical and biological features of acute myeloid leukemia occurring as a second malignancy: GIMEMA archive of adult acute leukemia. Br J Haematol 1999;106: 1037–1040.
   PubMed Web of Science ®Google Scholar
• Shivakumar R, Tan W, Wilding GE, et al. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia – a review of 101 cases. Ann Oncol 2008;19:1634–1638.
   PubMed Web of Science ®Google Scholar
• Abdulwahab A, Sykes J, Kamel-Reid S, et al. Therapy related acute lymphoblastic leukemia is more frequent than previously recognised and has a poor prognosis. Cancer 2012;118:3962–3967.
   PubMed Web of Science ®Google Scholar
• Tang G, Zuo Z, Thomas DA, et al. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy related? Haematologica 2012;97:919–925
   PubMed Web of Science ®Google Scholar
• Ganzel C, Devlin SM, Douer D, et al. Secondary ALL may be independent of prior cytotoxic therapy. 57 ASH Annual Meeting and Exposition,2014. Abstract 3648.
   Google Scholar
• Swaika A, Ailawadhi S, Yang M, et al. Secondary acute lymphoblastic leukemia after primary solid organ malignancy: a SEER analysis of incidence and outcomes. 57 ASH Annual Meeting and Exposition,2014. Abstract 935.
   Google Scholar
• Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.Haematologica 2005;90:1346–1356.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the pediatric-based protocol PETHEMA ALL-96. J Clin Oncol 2008;26:1843–1849.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, González M, et al, on behalf of the Programa Español de Tratamiento en Hematología (PETHEMA) and Grupo Español de Trasplante Hemopoyético (GETH) Groups. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2010;95:87–95.
   Google Scholar
• Ribera JM, García O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol 2012;159:78–81.
   PubMed Web of Science ®Google Scholar
• Ribera JM, García O, Fernández-Abellán P, et al. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols. Br J Haematol 2012;159:485–488.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol 2014;32:1595–1604.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Pullakart V, Dagis A, et al. Therapy-related acute lymphoblastic leukemia: cytogenetic features and hematopoietic stem cell transplantation outcome. 57 ASH Annual Meeting and Exposition,2014. Abstract 3655.
   Google Scholar
• Andersen MK, Christiansen DH, Jensen BA, et al. Therapy related acute lymphoblastic leukemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001;114:539–543.
   PubMed Web of Science ®Google Scholar
• Auxenfants E, Morel P, Lai JL, et al.Secondary acute lymphoblastic leukemia with t(4;11): report on two cases and review of the literature. Ann Hematol 1992;65:143–146.
   PubMed Web of Science ®Google Scholar
• Yoo BJ, Nam MH, Sung HJ, et al. A case of therapy related acute lymphoblastic leukemia with t(11;19)(q23;p13.3) and MLL/MLLT1 gene rearrangement. Korean J Lab Med 2011;31:13–17.
   PubMed Web of Science ®Google Scholar
• Lovett BD, Lo Nigro L, Rappaport E, et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proc Natl Acad Sci USA 2001;98:9802–9807.
   PubMed Web of Science ®Google Scholar
• Racke F, Cole C, Walker A, et al. Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification. Cancer Genet 2012;205:653–656.
   PubMed Web of Science ®Google Scholar
• Chen W, Wang E, Lu Y, et al. Therapy related acute lymphoblastic leukemia without 11q23 abnormality. Am J Clin Pathol 2010; 133:75–82.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et alDifferent molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J 2014 Jul 11;4:e225.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kneba M, Raff T, et al. German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868–1876.
   Google Scholar